Aptinyx Reaches Milestones, Raises $70m To Develop NMDA Modulators
Executive Summary
Aptinyx – spun out of Naurex in 2015 after it was acquired by Allergan – closed a Series B venture capital round that brought in new investors with a long-term view, the ability to support a future IPO and experience with neuroscience drugs.
You may also be interested in...
Aptinyx Says DPN Setback Just A Step In Seeking Chronic Pain Indication
Investors reacted negatively when Aptinyx’s lead candidate missed its primary endpoint in diabetic peripheral neuropathy, but CEO Riedel tries to emphasize the positives from the study while awaiting fibromyalgia data with NYX-2925.
J.P. Morgan Notebook Day 3: Biotech Feeling Government Shutdown, AstraZeneca, Denali, Allergan, Aptinyx, Sangamo
Daily round-up of news and notes from the 2019 J.P. Morgan Healthcare Conference in San Francisco: AstraZeneca's net prices set to slide in 2019; biotechs ponder disasters from government shutdown; Denali moves into gene therapy; Sangamo clarifies partnering strategy; and Scrip talks to Allergan and Aptinyx about upcoming NMDA data releases.
J.P. Morgan Notebook Day 3: Biotech Feeling Government Shutdown, AstraZeneca, Denali, Allergan, Aptinyx, Sangamo
Daily round-up of news and notes from the 2019 J.P. Morgan Healthcare Conference in San Francisco: AstraZeneca's net prices set to slide in 2019; biotechs ponder disasters from government shutdown; Denali moves into gene therapy; Sangamo clarifies partnering strategy; and Scrip talks to Allergan and Aptinyx about upcoming NMDA data releases.